Date: 2016-06-07
Type of information: Licensing agreement
Compound: LentiVector® platform technology patents
Company: Molmed (Italy) Oxford BioMedica (UK)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: gene therapy.
Disease:
Details: * On June 7, 2016, Oxford BioMedica announced that it has signed a new non-exclusive licence under Oxford BioMedica’s LentiVector® platform technology patents for manufacturing and development services with MolMed. A previous retroviral patent agreement between Oxford BioMedica and MolMed has now expired. This new agreement concerning lentiviral vector technology and considering recent expiration of relevant patents, terminated the existing exclusive licence agreement on retroviral patents. By means of the new licence agreement, Oxford BioMedica grants to MolMed a non-exclusive licence under its LentiVector® platform technology for manufacturing and development services.
At the same time, the parties terminated the agreement dated 10 December 2004 under which Oxford BioMedica granted MolMed a world-wide, exclusive licence on development and commercialisation of certain products in the field of genetically modified T lymphocytes transduced with retroviral vectors used in research and ex vivo gene therapy, including Zalmoxis® (TK). As a result of this agreement settlement, MolMed owes no outstanding royalties to Oxford BioMedica while keep using the above mentioned technology, in the ongoing development and potential commercialization of Zalmoxis® (TK).
Financial terms:
Latest news:
